Apogee Soars 47% After AbbVie Offers $10.9 Billion in Cash

Q: By doubling down on immunology, is AbbVie strategically ignoring the multi-billion dollar obesity drug market?

No. AbbVie is prioritizing immunology because it is where it already has scale, commercial strength and near-term visibility, not because it is abandoning obesity. The Apogee deal fits a clear post-Humira strategy: deepen AbbVie’s leadership in inflammatory disease with assets that can plug into its existing immunology franchise. Apogee’s lead programs in atopic dermatitis and asthma are clinically aligned with AbbVie’s strengths, and AbbVie expects the acquisition to add to adjusted earnings starting in 2032. With Skyrizi and Rinvoq already driving strong growth, this is a logical use of capital to reinforce a proven business. At the same time, AbbVie is not absent from obesity. It has reported positive Phase 1 data for ABBV-295, a long-acting amylin analog, and has described obesity as an emerging growth area. The company is also building obesity R&D capabilities and pursuing a differentiated non-GLP-1 approach rather than trying to enter the market head-on with a late me-too incretin drug. What is true is that AbbVie is behind the leaders in obesity. Eli Lilly and Novo Nordisk have a major head start, and AbbVie’s obesity effort remains early-stage, while its immunology investments are larger, more mature and closer to commercial payoff. So the strategic picture is not that AbbVie is ignoring obesity; it is sequencing its bets. It is doubling down where it has competitive advantage now, while making a smaller, earlier wager on obesity for longer-term diversification.

3 articles · Updated · The Motley Fool · Jun 22

Apogee Therapeutics jumped 46.66% to $132.55 after AbbVie agreed to buy the clinical-stage biotech for $135.11 a share in cash, lifting the stock to within about 2% of the offer price.
61.0 million shares changed hands—about 3,064% above Apogee's three-month average—as investors bet the transaction is likely to close on the expected Q3 2026 timeline.
AbbVie is buying Apogee to bolster its immunology pipeline with trial-stage treatments for asthma, atopic dermatitis and eosinophilic esophagitis, including lead drug zumilokibart.
The deal gives AbbVie a longer-term growth option beyond Rinvoq and Skyrizi, though investors still need to watch whether Apogee's less-frequent-dosing thesis holds up in clinical trials.

Sources

Left25%

Center75%

The Motley Fool63d ago

AbbVie Offers $10.9 Billion Cash for Apogee Therapeutics; Stock Soars

Yahoo Finance63d ago

AbbVie's biggest deal since 2019 could land soon

Yahoo Finance63d ago

AbbVie strikes $10.9 billion deal for Apogee Therapeutics

11 Sources

Is AbbVie's $10.9B deal a smart buy or just another symptom of the industry's 'patent cliff' panic?

By doubling down on immunology, is AbbVie strategically ignoring the multi-billion dollar obesity drug market?

AbbVie’s $10.9 Billion Acquisition of Apogee Therapeutics: Strategic Pipeline Expansion and the Race for Next-Gen Immunology Blockbusters

Overview

AbbVie announced on June 18, 2026, that it will acquire Apogee Therapeutics for $10.9 billion, aiming to strengthen its position and secure future growth in the immunology sector. The deal involves merging Andor Merger Co., a subsidiary of AbbVie, into Apogee, which will then operate as a wholly owned subsidiary. News of the acquisition quickly boosted Apogee’s share price by nearly 53% in pre-market trading. This strategic move highlights AbbVie’s commitment to expanding its immunology pipeline and maintaining leadership in a highly competitive market.

...